Erasca Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Are we good to go? Great. Hey, everyone. Thanks for joining us today. I'm here with Erasca CEO Jonathan Lim and CFO/CBO David Chacko. You guys have been quite busy over this last year, and you've certainly kept us on our toes as far as data disclosure cadence. Maybe to start, maybe a very brief introduction to the company. I think most are pretty familiar with you guys at this point, but where you guys are and milestones you have coming up near term.
Yeah. Thanks, Laura. Great to be here. Thanks, everyone. Erasca is a company that's entirely focused on erasing cancer and erasing the RAS-driven cancers as well. Both of those missions are in our name, Erasca. Our pipeline consists of two main programs. ERAS-0015 is our lead program, which is a pan-RAS molecular glue. It's being explored in the AURORAS-1 phase I trial, and we have a number of exciting developments there that we can talk about today. ERAS-4001 is our pan-KRAS switch II pocket binder. This is a small molecule that hits KRAS, but it spares H and N-RAS, and that's in a phase I trial as well called BOREALIS-1. The milestones that we have upcoming for both programs are, starting with BOREALIS-1, we have a phase I update that we've guided to the second half of this year.
Given that we're in the second half, it's going to happen soon. For ERAS-0015, we have an oral plenary presentation at the Triple Meeting in Barcelona next week. There's a lot of focus and attention on that readout. Also we've guided to combination data, including panitumumab for first half of next year. I mentioned the excitement around this program. We've also guided to three pivotal trials. One is a potentially registration-enabling trial in the second-line plus non-small cell lung cancer setting. There's RAS mutant lung, and this is one that could start as early as the first half of next year for ERAS-0015 monotherapy. We also are seeking combinations of ERAS-0015 with standard of care therapies.
For instance, we're combining with pembrolizumab, and we could take a chemo-free combo into the first-line RAS mutant lung setting as early as the second half of next year. Or we could choose to combine, once we find a dose for ERAS-0015 with pembro full dose, we could layer on chemotherapy and then take that checkpoint chemo combo with ERAS-0015 for the first-line RAS mutant lung setting, and that could start in first half of 2028. That's why we broadbanded that guidance for that trial between second half of 2027 and first half of 2028.
Have you guys disclosed if you've started adding chemo on top of 0015 plus pembro yet?
We haven't, but what we have said is that we started that pembro combo in Q2 of this year. The intention would be once we identify what the right dose is for ERAS-0015, the pharmacologically active dose, or PAD, if you will, is between 16 milligrams of ERAS-0015 on the low end. We've seen very good activity actually in non-small cell lung cancer. I think in the April disclosure, we had something like, in the U.S., five out of six patients had a response, which was really exciting to see. So 16 milligrams is an active dose, but if we can dose up to 24 to 32 milligrams, then we'd feel better about just having more drug on board. Once we identify the safe, tolerated, and efficacious dose of the doublet, then the intention is to layer on carboplatin and pemetrexed.
Got it. How involved is Merck with you in this process? They're providing free drug. Are they also helping with the dose selection process, or is this something you guys are doing independently?
We have a very good collaboration with Merck. They have visibility into what we're doing, and we don't do anything without making sure that they're informed and on board with what we're doing. But we're really driving the day-to-day activities as well as the strategic direction of what we're doing with ERAS-0015 and pembro.
Got it. After you showed us data in July, the guidance was for next dataset in 2027. What inspired or led to you guys submitting for an oral presentation at Triple Meeting, the one we're going to see next week?
Yeah, it's funny. To your point, things have been moving so quickly that anytime we think we're guiding to the next milepost, we actually are able to show another dataset, and it's never intentional. At the time, our guidance is what we genuinely believe, but then things happen and we're just enrolling at such a rapid clip that it's sometimes hard to keep up with the program, but it's really fun and exciting to keep up with it. I'd say for this one, the main impetus was actually driven more by audience. The April and July datasets were primarily geared to a corporate audience and less so to the scientific audience. I think for the oral presentation for the Triple Meeting, the stakeholders that we really want to get to are the thought leaders as well as the investigator community.
Because I'd say that the investigators that stay abreast of all the corporate developments in biotech land are very familiar with our data, but then those that are really sort of knee-deep in the day-to-day clinical work in their centers may not be familiar with our data. This really is intended to be a coming out party, so to speak, to the scientific community to make sure that we're on everyone's radar, so that they're very familiar with our lung and our pancreatic data. I will say that because we've been enrolling very quickly, I'd say that this would be a materially expanded update relative to what we've shown in April and even July.
Can you elaborate a little bit more on that point? Should we expect maybe double number of patients, enrichment for earlier line, especially in PDAC, second-line patients?
Yeah. Any context you can give us?
Yes. What we have said is that it will be a larger dataset. I think for efficacy evaluable patients in both pancreatic and lung, I think your double is a reasonable estimate. It will be at least that, so it will be at least double the patients. Especially we have been putting our thumb on the scale with respect to what we call the RDE. So within that PAD of 16-32 milligrams, 24 and 32 milligrams are the recommended doses for expansion, and we have been expanding those levels. You will see a lot more patients at those doses because we want to be able to, both for Project Optimus as well as for our own drug development internal decision-making purposes, pick a dose that is very rational to go forward with.
For instance, in lung cancer, which tends to be a more sensitive tumor type, you can see pretty good activity across a dose range. I think in a pretty relatively insensitive tumor type like pancreatic, that is where dose might matter a little more and getting especially exposure. With our molecule, historically we have shown that there is very good dose proportional increases in exposure as you go up in dose. So we do not have the exposure plateau that has been observed with other molecules in the class. I think with pancreatic, it will be important especially for us to see what do we observe at 32 milligrams versus 24 versus 16, et cetera. To answer the second part of your question, in terms of the composition of patients, we have not really been focused on earlier lines of treatment.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
